Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > An example of deceptive headlines for Adstiladrin
View:
Post by DJDawg on Dec 09, 2023 12:28pm

An example of deceptive headlines for Adstiladrin

https://www.medpagetoday.com/meetingcoverage/suo/107650

The headline is

First Gene Therapy for Non-Muscle-Invasive Bladder Cancer Offers Durable Response

— A quarter patients with high-risk, BCG-unresponsive disease were recurrence free at 3 years


Whereas what it should read is a quarter of those who responded AT ALL were recurrence free at 3 years.

Or it could read

12% of those initialy treated were recurrence free at 3 years.
Comment by Eoganacht on Dec 09, 2023 1:40pm
Yes - very deceptive. And this kind of thing is done a lot. If Theralase were to play that game and we end up with a 35% CRR at 3 years, our headline might read: More than one half of Theralase patients with high-risk BCG-unresponsive disease were recurrence free at 3 years
Comment by StevenBirch on Dec 09, 2023 2:38pm
Well let's hope the FDA sees through deceptive headlines like that, I'm sure they do just like I'm sure Roger knows they do. Doesn't TLT really have the trifecta - better CR numbers, fewer AE's and fewer/less invasive treatments than the competition? I'm going to assume that all companies in this field go through the same machinations and frustrations that we are going ...more  
Comment by Paradise818 on Dec 10, 2023 11:33am
I seriously doubt the FDA will see anything.  They are controlled by BIG pharma period.
Comment by DeathXray33 on Dec 10, 2023 5:18pm
Asstilladrin (a mess). Merc made a messtake... They shall soon see...
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250